Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZC8072 in Healthy Adults and Participants With Overweight or Obesity
NCT07784699Phase 1Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial in obesity comparing GZC8072 Tablets with Placebo (2 arms). Primary endpoints: Incidence of adverse events and serious adverse events at Day 57 and Immunogenicity: anti-drug antibodies and neutralizing antibodies at Day 57. Started Sep 2026; status: recruiting.
02
Drugs
GZC8072
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07784699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784699.